Whether this phenomenon can be attributed to a shift of the non-responding population away from the poor prognosis Residual Cancer Burden III class [27], to the eradication of minimal residual disease by prolonged adjuvant HER2-blockade, or to other factors is unclear. The gene discussed is ERBB2; the disease is cancer.